Syndax Historical Income Statement

SNDX Stock

USD 13.08 0.08 0.62%

Historical analysis of Syndax Pharmaceuticals income statement accounts such as Research Development of 196.8 M, Total Operating Expenses of 277.7 M, Total Other Income Expense Net of 24.9 M or Total Revenue of 0.0 can show how well Syndax Pharmaceuticals performed in making a profits. Evaluating Syndax Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Syndax Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Syndax Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Syndax Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

About Syndax Income Statement Analysis

Syndax Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Syndax Pharmaceuticals shareholders. The income statement also shows Syndax investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Syndax Pharmaceuticals Income Statement Chart

At this time, Syndax Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 277.7 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 13.1 K in 2025.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Syndax Pharmaceuticals. It is also known as Syndax Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Syndax Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Syndax Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.At this time, Syndax Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 277.7 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 13.1 K in 2025.

Syndax Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Interest Income	Net Interest Income	Non Operating Income Net Other	Reconciled Depreciation
Depreciation And Amortization		0.54	-0.33	-0.31	0.25	0.26	-0.29	0.26	-0.31	0.24	-0.46	0.24	0.36	-0.05	0.02	0.2	0.42	-0.5	-0.49	0.1	0.58
Interest Expense	0.54		0.02	0.04	-0.02	-0.01	0.08	-0.01	0.04	-0.05	-0.38	-0.04	-0.06	0.59	0.25	-0.1	0.15	-0.29	-0.36	0.49	0.12
Selling General Administrative	-0.33	0.02		0.99	-0.91	-0.9	0.99	-0.9	0.99	-0.89	0.88	-0.9	-0.87	0.11	0.03	-0.85	-0.18	0.94	0.91	0.79	-0.9
Other Operating Expenses	-0.31	0.04	0.99		-0.9	-0.9	1.0	-0.9	1.0	-0.89	0.87	-0.89	-0.87	0.17	0.06	-0.85	-0.19	0.93	0.89	0.81	-0.92
Operating Income	0.25	-0.02	-0.91	-0.9		1.0	-0.89	1.0	-0.9	1.0	-0.85	1.0	0.88	0.07	0.33	0.99	0.13	-0.9	-0.88	-0.69	0.79
Ebit	0.26	-0.01	-0.9	-0.9	1.0		-0.89	1.0	-0.9	1.0	-0.85	1.0	0.88	0.07	0.33	0.99	0.13	-0.9	-0.88	-0.69	0.8
Research Development	-0.29	0.08	0.99	1.0	-0.89	-0.89		-0.89	1.0	-0.88	0.85	-0.88	-0.87	0.22	0.09	-0.85	-0.19	0.91	0.87	0.83	-0.92
Ebitda	0.26	-0.01	-0.9	-0.9	1.0	1.0	-0.89		-0.9	1.0	-0.85	1.0	0.88	0.07	0.33	0.99	0.13	-0.9	-0.88	-0.69	0.8
Total Operating Expenses	-0.31	0.04	0.99	1.0	-0.9	-0.9	1.0	-0.9		-0.89	0.87	-0.89	-0.87	0.17	0.06	-0.85	-0.19	0.93	0.89	0.81	-0.92
Income Before Tax	0.24	-0.05	-0.89	-0.89	1.0	1.0	-0.88	1.0	-0.89		-0.82	1.0	0.87	0.06	0.35	0.99	0.12	-0.88	-0.86	-0.69	0.78
Total Other Income Expense Net	-0.46	-0.38	0.88	0.87	-0.85	-0.85	0.85	-0.85	0.87	-0.82		-0.83	-0.77	-0.19	-0.18	-0.78	-0.24	0.97	0.97	0.51	-0.84
Net Income	0.24	-0.04	-0.9	-0.89	1.0	1.0	-0.88	1.0	-0.89	1.0	-0.83		0.87	0.07	0.35	0.99	0.12	-0.89	-0.86	-0.69	0.78
Income Tax Expense	0.36	-0.06	-0.87	-0.87	0.88	0.88	-0.87	0.88	-0.87	0.87	-0.77	0.87		-0.25	0.08	0.86	0.16	-0.81	-0.77	-0.67	0.86
Total Revenue	-0.05	0.59	0.11	0.17	0.07	0.07	0.22	0.07	0.17	0.06	-0.19	0.07	-0.25		0.72	0.05	-0.15	-0.12	-0.2	0.4	-0.3
Gross Profit	0.02	0.25	0.03	0.06	0.33	0.33	0.09	0.33	0.06	0.35	-0.18	0.35	0.08	0.72		0.4	-0.09	-0.17	-0.21	0.28	-0.15
Net Income From Continuing Ops	0.2	-0.1	-0.85	-0.85	0.99	0.99	-0.85	0.99	-0.85	0.99	-0.78	0.99	0.86	0.05	0.4		0.12	-0.84	-0.81	-0.68	0.74
Cost Of Revenue	0.42	0.15	-0.18	-0.19	0.13	0.13	-0.19	0.13	-0.19	0.12	-0.24	0.12	0.16	-0.15	-0.09	0.12		-0.23	-0.19	-0.18	0.24
Interest Income	-0.5	-0.29	0.94	0.93	-0.9	-0.9	0.91	-0.9	0.93	-0.88	0.97	-0.89	-0.81	-0.12	-0.17	-0.84	-0.23		0.99	0.57	-0.89
Net Interest Income	-0.49	-0.36	0.91	0.89	-0.88	-0.88	0.87	-0.88	0.89	-0.86	0.97	-0.86	-0.77	-0.2	-0.21	-0.81	-0.19	0.99		0.51	-0.86
Non Operating Income Net Other	0.1	0.49	0.79	0.81	-0.69	-0.69	0.83	-0.69	0.81	-0.69	0.51	-0.69	-0.67	0.4	0.28	-0.68	-0.18	0.57	0.51		-0.62
Reconciled Depreciation	0.58	0.12	-0.9	-0.92	0.79	0.8	-0.92	0.8	-0.92	0.78	-0.84	0.78	0.86	-0.3	-0.15	0.74	0.24	-0.89	-0.86	-0.62

Click cells to compare fundamentals

Syndax Pharmaceuticals Account Relationship Matchups

Syndax Pharmaceuticals income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	2.4M	1.9M	3.1M	208K	239.2K	227.2K
Selling General Administrative	22.5M	25.2M	33.3M	54.3M	62.5M	65.6M
Other Operating Expenses	72.9M	113.5M	151.8M	230.0M	264.4M	277.7M
Operating Income	(71.4M)	26.2M	(151.8M)	(230.0M)	(207.0M)	(196.6M)
Ebit	(71.4M)	26.2M	(151.8M)	(230.0M)	(207.0M)	(196.6M)
Research Development	50.4M	88.2M	118.5M	163.0M	187.5M	196.8M
Ebitda	(71.3M)	26.3M	(151.7M)	(229.9M)	(206.9M)	(196.6M)
Total Operating Expenses	72.9M	113.5M	151.8M	230.0M	264.4M	277.7M
Income Before Tax	(73.2M)	24.9M	(149.3M)	(209.4M)	(188.4M)	(179.0M)
Total Other Income Expense Net	(1.7M)	(1.3M)	2.4M	20.6M	23.7M	24.9M
Net Income	(73.1M)	24.9M	(143.7M)	(209.4M)	(188.4M)	(179.0M)
Net Income From Continuing Ops	(73.2M)	24.9M	(149.3M)	(176.1M)	(158.5M)	(150.5M)
Net Income Applicable To Common Shares	(56.0M)	(77.1M)	24.9M	(149.3M)	(134.4M)	(127.7M)
Interest Income	841K	403K	5.9M	18.6M	21.4M	22.5M
Net Interest Income	(1.5M)	(1.5M)	2.7M	18.4M	21.2M	22.2M
Non Operating Income Net Other	(27K)	(79K)	622K	605K	695.8K	730.5K
Reconciled Depreciation	89K	43K	33K	12K	10.8K	10.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syndax Historical Income Statement

About Syndax Income Statement Analysis

Syndax Pharmaceuticals Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Syndax Pharmaceuticals income statement Correlations

Syndax Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Syndax Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for Syndax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income

Reconciled Depreciation	- 0.92	Total Operating Expenses
Reconciled Depreciation	- 0.92	Research Development
Reconciled Depreciation	- 0.92	Other Operating Expenses
Operating Income	- 0.91	Selling General Administrative
Interest Income	- 0.9	Ebitda
Total Operating Expenses	- 0.9	Ebitda